cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Immatics Nv
3 watching
Current Price
$8.31
$0.2
(2.47%)
logo-imtx
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
522.92M
52-Week High
52-Week High
13.6
52-Week Low
52-Week Low
5.75
Average Volume
Average Volume
0.21M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization522.92M
icon52-Week High13.6
icon52-Week Low5.75
iconAverage Volume0.21M
iconDividend Yield--
iconP/E Ratio--
What does the Immatics Nv do?
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company s TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Read More
News & Events about Immatics Nv.
Ticker Report
2 months ago
Surrozen (NASDAQ:SRZN Get Rating) and Immatics (NASDAQ:IMTX Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, earnings, institutional ownership, risk, ...
Globe Newswire
3 months ago
Houston, Texas and Tuebingen, Germany, October 10, 2022 Immatics N.V. (NASDAQ: IMTX, Immatics), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today that it has agreed to sell, by way of an underwritten ...
Globe Newswire
3 months ago
Company to host conference call today, October 10, at 8:30 am EDT / 2:30 pm CEST Clinical validation of PRAME as multi-tumor target with large potential for TCR-based therapies: confirmed responses in different solid cancers, in patients with high and low PRAME expressionUpdate covers data from 27 ...
Globe Newswire
4 months ago
TCER IMA402 is a next-generation, half-life extended TCR Bispecific targeting an HLA-A*02:01-presented peptide derived from PRAME In preclinical studies, IMA402 demonstrated enhanced anti-tumor activity in vivo and reduced T cell engager-associated toxicities as part of overall favorable in vitro ...
Frequently Asked Questions
Frequently Asked Questions
What is Immatics Nv share price today?
plus_minus_icon
Can Indians buy Immatics Nv shares?
plus_minus_icon
How can I buy Immatics Nv shares from India?
plus_minus_icon
Can Fractional shares of Immatics Nv be purchased?
plus_minus_icon
What are the documents required to start investing in Immatics Nv stocks?
plus_minus_icon
What is today’s traded volume of Immatics Nv?
plus_minus_icon
What is today’s market capitalisation of Immatics Nv?
plus_minus_icon
What is the 52-Week High and Low Range of Immatics Nv?
plus_minus_icon
What percentage is Immatics Nv down from its 52-Week High?
plus_minus_icon
What percentage is Immatics Nv up from its 52-Week Low?
plus_minus_icon
Current Price
$8.31
$0.2
(2.47%)
logo-imtx
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00